On July 29, Huatai Bio's recigenimab was approved in China as the first domestically developed new drug for generalized pustular psoriasis (GPP) in adults. The approval marks the first local launch of a treatment for this rare disease. The drug adds to a series of innovations from Pudong-based companies.
The US FDA has approved Novartis's Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), roughly doubling the eligible patient population. In the PSMAddition study, Pluvicto plus standard of care (ADT plus ARPI) reduced the risk of disease progression or death by 33% versus standard of care alone, with a positive overall survival trend (HR=0.80). About half of men with mHSPC progress within 20 months.